A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile

PURPOSE: The aim of this study was to evaluate the cost effectiveness of cladribine compared with alemtuzumab, natalizumab, and ocrelizumab for the treatment of highly active multiple sclerosis (HAD-MS) from the perspective of the Chilean health care public sector. MATERIALS AND METHODS: A Markov mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Espinoza, Manuel Antonio, Rojas, Rubén, Zaupa, Alessandro, Balmaceda, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611154/
https://www.ncbi.nlm.nih.gov/pubmed/34224114
http://dx.doi.org/10.1007/s41669-021-00282-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611154/
https://www.ncbi.nlm.nih.gov/pubmed/34224114
http://dx.doi.org/10.1007/s41669-021-00282-7

Ejemplares similares